Saba Shaikh, MD, talks with Komal Jhaveri, MD, about the results of the ASCENT-07 study, which demonstrated that patients with HR-positive, HER2-negative advanced breast cancers had similar progression-free survival whether they were treated with sacituzumab govitecan-hziy or standard-of-care chemotherapy as the first treatment after endocrine therapy.
▷ Estimated Read Time:
1–2 minutes
SABCS Snippets: Results from the Phase III ASCENT-07 Trial
Connect with thousands of basic and translational scientists, multidisciplinary clinicians, regulatory and pharmaceutical partners, survivors, and patient advocates at the 49th annual San Antonio Breast Cancer Symposium. Complete your registration by Friday, September 25, to take advantage of discounted early registration rates.
Share: